6 completed, 2 active not recruiting, 1 recruiting, 1 unknown. 10 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 6, Active not recruiting 2, Recruiting 1, Unknown 1 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Glioblastoma Multiforme of Brain: new trials by email Literature Review of Glioblastoma Multiforme of Brain trials Research Report on Glioblastoma Multiforme of Brain
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma Ruxolitinib, Temozolomide, Radiation Therapy - Glioblastoma, Brain Cancer | Phase 2 | Recruiting | Baptist Health South Florida | 190 | 2025-12-03 | 2026-10-02 |
| Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma Cisplatin Plus Temozolomide, Temozolomide - Glioblastoma Multiforme of Brain | Phase 1 / Phase 2 | Unknown | Zhongnan Hospital | 60 | 2024-01-01 | 2024-01-02 |
| Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) TVI-Brain-1, Standard of Care, Radiotherapy - Glioblastoma Multiforme of Brain | Phase 2 / Phase 3 | Active not recruiting | TVAX Biomedical | 120 | 2023-12-27 | 2026-09-29 |
| Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma IMA950/Poly-ICLC, IMA950/Poly-ICLC and pembrolizumab - Glioblastoma Multiforme, Glioblastoma, Adult | Phase 1 / Phase 2 | Completed | University Hospital, Geneva | 18 | 2018-10-25 | 2025-05-13 |
| Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme avelumab - Glioblastoma Multiforme of Brain | Phase 2 | Completed | Clinique Neuro-Outaouais | 38 | 2017-05-19 | 2025-05-25 |
| Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients Dendritic cell vaccine plus temozolomide chemotherapy - Glioblastoma Multiforme of Brain | Phase 1 / Phase 2 | Active not recruiting | University Hospital, Antwerp | 20 | 2015-12-01 | 2026-06-04 |
| Effect of Deep TMS on the Permeability of the BBB in Patients With Glioblastoma Multiforme: a Pilot Study Deep Transcranial Magnetic Stimulation (dTMS) - Glioblastoma Multiforme of Brain | Phase 2 | Completed | University of Roma La Sapienza | 15 | 2014-11-01 | 2015-06-18 |
| MRSI to Predict Response to RT/TMZ ± Belinostat in GBM Standard Radiation Therapy, Standard Temozolomide, Belinostat - Glioblastoma Multiforme of Brain | Phase 2 | Completed | Emory University | 29 | 2014-05-07 | 2026-10-30 |
| Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study Ketogenic Diet, Standardized Diet - Glioblastoma Multiforme of Brain | Phase 2 | Completed | Mid-Atlantic Epilepsy and Sleep Center, LLC | 42 | 2014-02-01 | 2022-08-11 |
| Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme Antineoplaston therapy (Atengenal + Astugenal) - Glioblastoma Multiforme of Brain | Phase 2 | Completed | Burzynski Research Institute | 40 | 1995-03-14 | 2018-03-22 |
Glioblastoma (4) · Brain Neoplasms (1)
Astrocytoma (4) · Glioma (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Glandular and Epithelial (4) · Neoplasms, Nerve Tissue (4) · Neoplasms, Neuroepithelial (4) · Neuroectodermal Tumors (4) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Neoplasms by Site (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1)
Temozolomide (4) · Radiotherapy (2) · Cisplatin (1) · Diet, Ketogenic (1) · Drug Therapy (1) · Standard of Care (1) · antineoplaston A10 (1) · antineoplaston AS 2-1 (1) · avelumab (1) · belinostat (1) · pembrolizumab (1) · ruxolitinib (1)
Baptist Health South Florida (1) · Burzynski Research Institute (1) · Clinique Neuro-Outaouais (1) · Emory University (1) · Mid-Atlantic Epilepsy and Sleep Center, LLC (1) · TVAX Biomedical (1) · University Hospital, Antwerp (1) · University Hospital, Geneva (1) · University of Roma La Sapienza (1) · Zhongnan Hospital (1)
United States (5) · Belgium (1) · Canada (1) · Switzerland (1)
Gary Wood, PhD (1) · Hui-Kuo Shu, MD, PhD (1) · Manmeet Ahluwalia, M.D., MBA (1) · Marika Rasschaert, MD, PhD (1) · Maurizio Inghilleri, Professor (1) · Nicolas Mach, Prof. (1) · Pavel Klein, M.D. (1) · Stanislaw R. Burzynski, MD, PhD (1) · Zwi N Berneman, MD, PhD (1)
PMID 12436090, PMID 12743250, PMID 12893641, PMID 15717053, PMID 15792886, PMID 18798293, PMID 19664713, PMID 19682584, PMID 19833552, PMID 21924290, PMID 22037136, PMID 22629405, PMID 23388348, PMID 25117977, PMID 33292598, PMID 34604752, PMID 404164
F30CA206291 (1), P30CA138292 (1), R21NS100244 (1), U01CA172027 (1)